Cep123: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: CEP89

NCBI ID: G84902

CEP89

Cep123: A Potential Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50 million adults experience chronic pain, which costs the global economy $600 billion annually. Chronic pain can be caused by various conditions, including musculoskeletal, neuropathic, and psychiatric disorders. While conventional pain treatments such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioid analgesics have been effective in managing chronic pain, they often have limited efficacy and potential for abuse. As such, there is an ongoing need for new and innovative pain treatments that can provide lasting relief without negative side effects.

CEP89 (Cep123) is a novel protein that has been identified as a potential drug target and biomarker for chronic pain. Cep123 is a 123-kDa protein that is expressed in various tissues, including brain, muscle, and peripheral tissues. It is a member of the superfamily of cytoplasmic efflux proteins (CEP), which are involved in the rapid transfer of small molecules across cell membranes. Cep123 is unique due to its structural and functional domain diversity, including a N-terminal transmembrane domain, a T- loop region, a N-terminal cytoplasmic domain, and a C-terminal protein-coding domain.

CEP89 functions as a protein that can modulate the activity of other proteins, particularly those involved in pain signaling pathways. It has been shown to interact with several pain-related proteins, including cyclic AMP-response element-converting enzyme (CRE), calcitonin, and neuropeptide Y. These interactions may modulate the activity of these proteins and contribute to the potential therapeutic effects of CEP89.

In addition to its potential role in pain signaling pathways, CEP89 has also been shown to have potential as a biomarker for chronic pain. Chronic pain is often associated with inflammation, which can be evaluated using various biomarkers, including cytokines, chemokines, and pain- related factors such as pain perception and thermal nociception. CEP89 has been shown to be involved in the regulation of these biomarkers, which may make it an attractive biomarker for the diagnosis and monitoring of chronic pain.

CEP89 has also been shown to have potential as a drug target for chronic pain. Its unique structure and function domain, as well as its interactions with pain-related proteins, make it an attractive target for small molecules. Several small molecules have been shown to interact with CEP89, including inhibitors of the enzyme inhibitors (IIS) family, which are involved in the regulation of pain signaling pathways. These interactions may indicate that CEP89 is involved in the regulation of pain signaling pathways and may be a potential drug target for chronic pain.

Conclusion

CEP89 is a novel protein that has been identified as a potential drug target and biomarker for chronic pain. Its unique structure and function domain, as well as its interactions with pain-related proteins, make it an attractive target for small molecules. Further research is needed to fully understand the role of CEP89 in pain signaling pathways and its potential as a drug target for chronic pain. If proven to be effective, CEP89 may provide a new and effective treatment for chronic pain, leading to improved quality of life for millions of people worldwide.

Protein Name: Centrosomal Protein 89

Functions: Required for ciliogenesis. Also plays a role in mitochondrial metabolism where it may modulate complex IV activity

The "CEP89 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CEP89 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets